Lymphoma
Cutaneous T-Cell:
IRB #H-30213: Phase II Trial of the MTOR Inhibitor Everolimus in Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)
IRB #H-31765/Millennium C25001: A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Hodgkin’s Lymphoma:
Hodgkin’s Disease:
IRB #H-31396/AMC #079: : Quantification of HIV-1 Reservoirs in HIV-Positive Persons Receiving Response-Adapted Therapy for Stage III-IV Hodgkin Lymphoma: A Companion Protocol to SWOG Protocol S0816 (AMC-073)
Peripheral T-Cell:
IRB #H-29661/Allos: Prospective, Longitudinal, Multinational Registry of Patients with
Newly Diagnosed Peripheral T-Cell Lymphoma (temporarily closed)
Lymphoid Malignancies:
IRB #H-26640: Telomere DNA-Based experimental Analysis of Lymphoid Malignancy
(Contact G.Denis @ 4-1371)
Diffuse Large B-Cell:
IRB #H-31387/SWOG #S0806: A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)
Patients Undergoing Stem Cell Transplantation:
IRB #2006-1918/Merck V212: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)
